Eli Lilly's sales idled for years, then took off
Free, six mornings a week · Unsubscribe in one click
What the chart shows
Here is Eli Lilly's revenue for the July-to-September quarter in every year since 2008.
It was US$5.2bn in 2008 and US$6.9bn in 2022. Then came US$9.5bn, US$11.4bn and US$17.6bn, and on Thursday Lilly reported US$24.4bn, 39% more than a year earlier.
Mounjaro brought in US$10.7bn of the latest quarter and Zepbound US$5.3bn. Each new market Lilly wins pays less per dose, so the growth rests on how many doses it sells. The company raised its full-year revenue forecast to between US$91bn and US$92bn, from US$85bn to US$87bn.
The story behind it
Eli Lilly closed at a record after its weight-loss drugs lifted sales 39% Read the edition →Eli Lilly on the calendar
Next results: date to come. It goes on the calendar as soon as Eli Lilly announces it. Economic calendar →The numbers
Eli Lilly's revenue in the July-to-September quarter of each year, 2008 to 2026, in US$bn. This year's US$24.4bn was 39% more than a year earlier.
| Revenue, July-September quarter | Dot | |
|---|---|---|
| Q3 2008 | 5.2 | |
| Q3 2009 | 5.6 | |
| Q3 2010 | 5.7 | |
| Q3 2011 | 6.1 | |
| Q3 2012 | 5.4 | |
| Q3 2013 | 5.8 | |
| Q3 2014 | 4.9 | |
| Q3 2015 | 5.0 | |
| Q3 2016 | 5.2 | |
| Q3 2017 | 5.0 | |
| Q3 2018 | 5.3 | |
| Q3 2019 | 5.5 | |
| Q3 2020 | 5.7 | |
| Q3 2021 | 6.8 | |
| Q3 2022 | 6.9 | |
| Q3 2023 | 9.5 | |
| Q3 2024 | 11.4 | |
| Q3 2025 | 17.6 | |
| Q3 2026 | 24.4 |
19 rows: scroll the table for the rest.
How we make these charts: one chart a day from a story in the edition, drawn from the figures the story names and checked against the sources named on the chart before it is published. General information only, not financial advice.
